Protocatechualdehyde
CAS 139-85-5
Protocatechualdehyde (CAS 139-85-5) is a pharmaceutical compound with 6 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 27852.941176470587 nM | 17 | - |
| - | Potency | 17788.678571428572 nM | 14 | - |
| - | GI50 | 74166.66666666667 nM | 6 | - |
| - | EC50 | 3.2 ug.mL-1 | 2 | - |
| - | IC50 | 2.285 ug.mL-1 | 2 | - |
| - | EC50 | 6570 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Protocatechualdehyde used for in pharmaceutical contexts?
Protocatechualdehyde (CAS 139-85-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Protocatechualdehyde?
No adverse-event association or SIDER side-effect rows are rendered for Protocatechualdehyde in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Protocatechualdehyde also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Protocatechuicaldehyde with EU status "permitted".
What clinical phase is Protocatechualdehyde in?
No phase 1-4 clinical development badge is rendered for Protocatechualdehyde because the matched compound identifier rows do not contain a max-phase value.